Year: 2022

BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024ADELAIDE, Australia, Dec. 18, 2022 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced results from its Phase 2 randomised, double-blind, placebo-controlled,...

CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022. The schedule for the press release and conference call/webcast is as follows:• MAESTRO-NASH Press Release:   December 19th, 2022 at 7:00 am EST• MAESTRO-NASH Conference Call:     December 19th, 2022 at 8:00 am EST     To access the live webcast of the call with slides please visit the Investors section of Madrigal’s website or click here. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants...

MACAU, Dec. 18, 2022 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner and operator of integrated resort facilities in Asia and Europe, today announces further details of the ten-year concession to operate games of fortune and chance in casinos in Macau (“Concession”) granted to Melco Resorts (Macau) Limited (“Melco Resorts Macau” or “Concessionaire”), a subsidiary of the Company, as announced on December 16, 2022.  The Concession is granted by the Macau Special Administrative Region of the People’s Republic of China (“Macau SAR”) to Melco Resorts Macau as the Concessionaire. The term of the Concession commences on January 1, 2023 and ends on December 31, 2032. Under the Concession, Melco Resorts Macau is authorised to operate the Altira Casino, the City...

WINDSOR, BERKSHIRE, United Kingdom, Dec. 17, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Argentum 47, Inc. (“Argentum” or the “Company”) (www.argq.io) (OTC PINK: ARGQ), a provider of comprehensive artificial intelligence enhanced digital marketing services including branding, advertising, and lead generation, announced today a correction statement in regards to the previous press release that was issued on December 15, 2022. Prior to the release, Argentum and Freuds Bazaar had engaged in conversation, there are no direct links between any of the parties listed. An announcement should not have been made prematurely. As a result of this error, Argentum is issuing a clarification statement for any misunderstandings that may have arisen between all parties. The Company noted that there is no direct link between...

Company Announcement, Helsinki, 17 December 2022 at 7.15 PM (EET) Nexstim Plc: Changes in the management team – Henri Hannula appointed as VP, Sales and Marketing Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that Steve Beller has decided to leave his position as the Vice President and General Manager, North America, effective immediately. Nexstim’s Board of Directors has appointed Henri Hannula (born 1974) as Vice President, Sales and Marketing responsible for these functions globally. He has held key leadership positions since joining Nexstim in 2001, most recently as responsible for EU & ROW sales and marketing. Mikko Karvinen, CEO of Nexstim Plc will continue in his role as President, Nexstim, Inc. “I want to thank Steve for his significant contribution to the company. During...

Palo Alto, California, Dec. 16, 2022 (GLOBE NEWSWIRE) — Epiphany Technology Acquisition Corp. (the “Company”) announced today that it will be unable to consummate an initial business combination and intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Certificate of Incorporation, as amended (“Liquidation”). On November 29, 2022, the Company filed with the Securities and Exchange Commission a definitive proxy statement (the “Proxy Statement”) in connection with a special meeting in lieu of an annual meeting of the stockholders (the “Meeting”) to consider and vote on certain proposals, including an extension of the date by which the Company has to complete an initial business combination from January 12, 2023 to July 12, 2023 (the “Extension”), as supplemented on December 13, 2022. At the...